On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...

U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its long-awaited non-opioid ...

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx (suzetrigine) ...

Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...

The FDA approved Vertex Pharmaceuticals' Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...

A new type of non-opioid painkiller, aimed at treating short-term pain in adults, has been approved by the US Food and Drug Administration (FDA). The drug suzetrigine, known by its brand name Journavx ...

The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...